Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.

J Immunother Cancer · 2021 · PMC8395363 · PMID 34446577

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

showed a trendp=0.068so close (0.05 < p ≤ 0.1)

However, despite the low number of cases, the presence of ARID1A mutations showed a trend to be associated to Pn development (p=0.068).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.